TCG Crossover holds 5.7% Amylyx Pharmaceuticals (AMLX) passive stake
Rhea-AI Filing Summary
Amylyx Pharmaceuticals Inc. received an updated ownership filing showing that investment entities affiliated with TCG Crossover hold a significant passive stake in its common stock. TCG Crossover Fund II, L.P., together with its general partner TCG Crossover GP II, LLC and Chen Yu, report beneficial ownership of 6,243,812 shares.
This position represents 5.7% of Amylyx’s outstanding common stock, based on 109,819,659 shares outstanding as of October 27, 2025. The reporting parties state they share voting and dispositive power over these shares and certify the holdings are not for the purpose of changing or influencing control of the company.
Positive
- None.
Negative
- None.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What percentage of Amylyx Pharmaceuticals (AMLX) does TCG Crossover report owning?
TCG Crossover-affiliated entities report beneficial ownership of 5.7% of Amylyx Pharmaceuticals’ common stock. This corresponds to 6,243,812 shares, based on 109,819,659 shares outstanding as of October 27, 2025, as cited from the company’s Form 10-Q.
Is the TCG Crossover stake in Amylyx (AMLX) a control or activist position?
The reporting parties certify the shares were not acquired to change or influence control of Amylyx. They file on Schedule 13G/A, which is typically used for passive investments, and explicitly state the holdings are not in connection with transactions aimed at control.
Who are the reporting persons in the Amylyx (AMLX) Schedule 13G/A amendment?
The reporting persons are TCG Crossover Fund II, L.P., its general partner TCG Crossover GP II, LLC, and Chen Yu. The entities are organized in Delaware, and Chen Yu is identified as a U.S. citizen and sole managing member of the general partner.
Do TCG Crossover and Chen Yu claim group status in their Amylyx (AMLX) filing?
The filing explicitly states the reporting persons disclaim status as a group for Schedule 13G purposes. They also disclaim beneficial ownership of securities not held directly, except to the extent of their pecuniary interest through the fund and general partner structures.